← Organizations
Company
Auris Medical
Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.
Programs
2
linked to organization
Strong Evidence
0
2 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
2 / 0
industry vs non-industry records
Competitive Density
3
Pipeline Velocity
30
Completion Signal
100
Programs by Stage
Phase 32
Trial / Program Status
Discontinued2
Modality Mix
Biologic1
Small Molecule1
Indication Coverage
Hearing Loss1
Sensorineural Hearing Loss1
Sudden Sensorineural Hearing Loss1
Tinnitus1
Program Types
Therapeutic2
Population Tags
adult2
profound1
sudden1
tinnitus1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksAM-111 by Auris Medical and Altamira
Status confirmed
BiologicPhase 3Discontinued
Intratympanic cell-penetrating peptide JNK inhibitor designed to protect cochlear cells in acute inner-ear hearing loss.
AM-101 by Auris Medical and Altamira
Status confirmed
Small MoleculePhase 3Discontinued
Intratympanic NMDA receptor antagonist gel was designed to treat acute inner-ear tinnitus after cochlear injury.